Syracuse

Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3–dependent sensitization

Archive ouverte

Jurczak, Alexandra | Delay, Lauriane | Barbier, Julie | Simon, Nils | Krock, Emerson | Sandor, Katalin | Agalave, Nilesh, M | Rudjito, Resti | Wigerblad, Gustaf | Rogóż, Katarzyna | Briat, A. | Miot-Noirault, Elisabeth | Martinez-Martinez, Arisai | Brömme, Dieter | Grönwall, Caroline | Malmström, Vivianne | Klareskog, Lars | Khoury, Spiro | Ferreira, Thierry | Labrum, Bonnie | Deval, Emmanuel | Jiménez-Andrade, Juan Miguel | Marchand, Fabien | Svensson, Camilla, I

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. Several bone conditions, eg, bone cancer, osteoporosis, and rheumatoid arthritis (RA), are associated with a risk of developing persistent pain. Increased osteoclast activity is often the hallmark of these bony pathologies and not only leads to bone remodeling but is also a source of pronociceptive factors that sensitize the bone-innervating nociceptors. Although historically bone loss in RA has been believed to be a consequence of inflammation, both bone erosion and pain can occur years before the symptom onset. Here, we have addressed the disconnection between inflammation, pain, and bone erosion by using a combination of 2 monoclonal antibodies isolated from B cells of patients with RA. We have found that mice injected with B02/B09 monoclonal antibodies (mAbs) developed a long-lasting mechanical hypersensitivity that was accompanied by bone erosion in the absence of joint edema or synovitis. Intriguingly, we have noted a lack of analgesic effect of naproxen and a moderate elevation of few inflammatory factors in the ankle joints suggesting that B02/B09-induced pain-like behavior does not depend on inflammatory processes. By contrast, we found that inhibiting osteoclast activity and acid-sensing ion channel 3 signaling prevented the development of B02/B09-mediated mechanical hypersensitivity. Moreover, we have identified secretory phospholipase A2 and lysophosphatidylcholine 16:0 as critical components of B02/B09-induced pain-like behavior and shown that treatment with a secretory phospholipase A2 inhibitor reversed B02/B09-induced mechanical hypersensitivity and bone erosion. Taken together, our study suggests a potential link between bone erosion and pain in a state of subclinical inflammation and offers a step forward in understanding the mechanisms of bone pain in diseases such as RA.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion